CN Patent
CN105085571A — 替诺福韦艾拉酚胺复合物及其制备方法和用途
Assigned to Sichuan Haisco Pharmaceutical Co Ltd · Expires 2015-11-25 · 10y expired
What this patent protects
本发明涉及式Ⅱ所示的替诺福韦艾拉酚胺复合物。本发明还涉及所述替诺福韦艾拉酚胺复合物的制备方法,含有该替诺福韦艾拉酚胺复合物的药物组合物,以及该替诺福韦艾拉酚胺复合物在制备预防和/或治疗病毒感染,特别乙型肝炎病毒(HBV)和/或人类免疫缺陷病毒(HIV)感染的药物中的应用。
USPTO Abstract
本发明涉及式Ⅱ所示的替诺福韦艾拉酚胺复合物。本发明还涉及所述替诺福韦艾拉酚胺复合物的制备方法,含有该替诺福韦艾拉酚胺复合物的药物组合物,以及该替诺福韦艾拉酚胺复合物在制备预防和/或治疗病毒感染,特别乙型肝炎病毒(HBV)和/或人类免疫缺陷病毒(HIV)感染的药物中的应用。
Drugs covered by this patent
- Emtriva (EMTRICITABINE) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.